AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29531754 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 212
Study 29531754 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212
Study 29531756 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-8059
Number of subjects: 24
Study 29531756 — intervention group
Group type: COMPARATOR
Intervention: CACS=0
Number of subjects: 24
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 as a continuous variable
Number of subjects: 262
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in inflammatory and/or viral DCM subgroup
Number of subjects: 262
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in idiopathic DCM subgroup
Number of subjects: 262
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in multivariate model
Number of subjects: 262
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 as a continuous variable
Number of subjects: 262
Study 29531765 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 in quartile model
Number of subjects: 262
Study 29531766 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212
Study 29531766 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 1212
Study 29531766 — intervention group
Group type: COMPARATOR
Intervention: CABG vs MED
Number of subjects: 1212
Study 29531780 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 165
Study 29531784 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad (2.5-20 mg) plus allopurinol (300 mg once daily)
Number of subjects: 41
Study 29531784 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg once daily, 600 mg once daily, or 300 mg twice daily)
Number of subjects: 41
Study 29531837 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line panitumumab plus chemotherapy followed by second-line VEGFi
Number of subjects: 104
Study 29531837 — intervention group
Group type: COMPARATOR
Intervention: First-line bevacizumab followed by second-line EGFRi
Number of subjects: 104
Study 29531839 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant/neoadjuvant chemotherapy
Number of subjects: 289
Study 29531839 — intervention group
Group type: COMPARATOR
Intervention: None (control group, did not receive chemotherapy)
Number of subjects: 289
Study 29532104 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3008348, single doses of 1-3000 mcg administered by nebulisation
Number of subjects: 29
Study 29532104 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3008348, single doses of 300-3000 mcg administered by nebulisation
Number of subjects: 29
Study 29532243 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal healthy bone behaviors (HBB) education including a healthy bones prescription (BoneRx), face-to-face education, and customized educational materials.
Number of subjects: 103
Study 29532243 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 103
Study 29533307 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous video-EEG (cEEG) for 30 to 48 hours
Number of subjects: 348
Study 29533307 — intervention group
Group type: COMPARATOR
Intervention: Routine EEG (rEEG)
Number of subjects: 348
Study 29533369 — intervention group
Group type: EXPERIMENTAL
Intervention: MLE4901 (NK3R antagonist)
Number of subjects: 37
Study 29533458 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) at a maximum tolerated dose (MTD) of 3.0 mg/kg.
Number of subjects: 56
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-resistant (FQ-R) E. coli strains
Number of subjects: 359
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin-resistant (3GC-R) E. coli strains
Number of subjects: 359
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-spectrum β-lactamase (ESBL)-producing E. coli strains
Number of subjects: 359
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: International travel
Number of subjects: 359
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antibiotics during the previous year
Number of subjects: 359
Study 29533507 — intervention group
Group type: EXPERIMENTAL
Intervention: 3GC-R E. coli strains
Number of subjects: 359
Study 29533531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for 5 months
Number of subjects: 189
Study 29533710 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (Blood Builder®/Iron Response®) containing 26 mg of iron, vitamin C, folate, and other nutrients, taken once daily for 8 weeks.
Number of subjects: 23
Study 29533755 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (4 mg/kg every 4 weeks)
Number of subjects: 301
Study 29534064 — intervention group
Group type: EXPERIMENTAL
Intervention: AF genetic risk score (GRS)
Number of subjects: 904
Study 29534170 — intervention group
Group type: EXPERIMENTAL
Intervention: Portico TAVI system
Number of subjects: 198
Study 29534171 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCS)
Number of subjects: 1002
Study 29534198 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDOPA PET/CT
Number of subjects: 6
Study 29534198 — intervention group
Group type: COMPARATOR
Intervention: CT/magnetic resonance imaging
Number of subjects: 6
Study 29534198 — intervention group
Group type: COMPARATOR
Intervention: 68Ga-DOTA,Tyr3-octreotate PET/CT
Number of subjects: 6
Study 29534198 — intervention group
Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose PET/CT
Number of subjects: 6
Study 29534240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality (measured by Pittsburgh Sleep Quality Index [PSQI])
Number of subjects: 1341
Study 29534240 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk for obstructive sleep apnea (OSA; assessed by Berlin questionnaire)
Number of subjects: 1341
Study 29534240 — intervention group
Group type: COMPARATOR
Intervention: Demographics and smoking history, disease severity (forced expiratory volume 1 s; 6 min walk test)
Number of subjects: 1341
Study 29534336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of prednisolone
Number of subjects: 0
Study 29534336 — intervention group
Group type: COMPARATOR
Intervention: Partial GC receptor agonist
Number of subjects: 0
Study 29534336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with systemic lupus erythematosus and rheumatoid arthritis
Number of subjects: 0
Study 29534442 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula, breastmilk, and infant cereals
Number of subjects: 2560
Study 29534442 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed and mixed-fed infants
Number of subjects: 2560
Study 29534442 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 2560
Study 29534442 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intakes per day (kcal)
Number of subjects: 2560
Study 29534442 — intervention group
Group type: EXPERIMENTAL
Intervention: Other main energy and carbohydrate sources
Number of subjects: 2560
Study 29534442 — intervention group
Group type: EXPERIMENTAL
Intervention: Other main protein and total fat sources
Number of subjects: 2560
Study 29534680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Assessment Tool (BAT)
Number of subjects: 85
Study 29534680 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Geriatric Assessment (C)
Number of subjects: 85
Study 29534703 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendoscopic enteral tubing (TET) procedure
Number of subjects: 86
Study 29534703 — intervention group
Group type: COMPARATOR
Intervention: Training of general endoscopists
Number of subjects: 86
Study 29534721 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208S (3 doses, 10 unspecified dosage)
Number of subjects: 0
Study 29534721 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208S
Number of subjects: 0
Study 29535081 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based behavioral intervention via mobile app (Type 1 Doing Well)
Number of subjects: 82
Study 29535141 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF) defined as an absolute increase in creatinine of ≥0.3 mg/dL.
Number of subjects: 5625
Study 29535141 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient WRF defined as recovery of creatinine at discharge.
Number of subjects: 5625
Study 29535141 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent WRF indicated by a nonrecovered creatinine level.
Number of subjects: 5625
Study 29535141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse in-hospital and follow-up outcomes associated with WRF.
Number of subjects: 5625
Study 29535451 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion (NB32)
Number of subjects: 36
Study 29535451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29535545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ledipasvir for 12 weeks
Number of subjects: 200
Study 29535545 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir plus oral weight-based ribavirin for 24 weeks
Number of subjects: 200
Study 29535712 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) with CN54gp140 vaccine, administered intramuscularly three times at 1-month intervals.
Number of subjects: 14
Study 29535869 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothie drink with 2 grams of plant stanols (Nutrive Benecol®) and dietary advice
Number of subjects: 99
Study 29535869 — intervention group
Group type: COMPARATOR
Intervention: Control drink and dietary advice
Number of subjects: 99
Study 29535915 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary care model
Number of subjects: 526
Study 29535915 — intervention group
Group type: COMPARATOR
Intervention: Serial care arm
Number of subjects: 526
Study 29536342 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Methadone Treatment (PCM)
Number of subjects: 8
Study 29536342 — intervention group
Group type: COMPARATOR
Intervention: Typical Treatment Sessions
Number of subjects: 8
Study 29536526 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg once daily for non-Asian patients aged ≥ 6 years
Number of subjects: 168
Study 29536526 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for Asian patients, regardless of age
Number of subjects: 168
Study 29536526 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for all patients aged 1-5 years, regardless of ethnic origin
Number of subjects: 168
Study 29536526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation at 2-week intervals or reduction as needed based on platelet counts
Number of subjects: 168
Study 29536781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0
Study 29536781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29537178 — intervention group
Group type: COMPARATOR
Intervention: Respondent-driven sampling
Number of subjects: 1929
Study 29537178 — intervention group
Group type: COMPARATOR
Intervention: Community-based recruitment
Number of subjects: 1929
Study 29537178 — intervention group
Group type: COMPARATOR
Intervention: Online advertising
Number of subjects: 1929
Study 29537178 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 1929
Study 29537325 — intervention group
Group type: EXPERIMENTAL
Intervention: oestradiol valerate/dienogest
Number of subjects: 66
Study 29537325 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinylestradiol/drospirenone
Number of subjects: 66
Study 29537325 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 66
Study 29537444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% adapalene and 2.5% benzoyl peroxide gel plus oral doxycycline 100 mg twice daily
Number of subjects: 186
Study 29537906 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy (RT) alone, n = 157
Number of subjects: 321
Study 29537906 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative concurrent chemoradiotherapy (CRT), n = 153
Number of subjects: 321
Study 29537906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (RT and CRT)
Number of subjects: 321
Study 29538667 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment without behavioral recommendations provided to the parent
Number of subjects: 125
Study 29538667 — intervention group
Group type: EXPERIMENTAL
Intervention: Close interpersonal ties among dyads
Number of subjects: 125
Study 29538669 — intervention group
Group type: EXPERIMENTAL
Intervention: RET fusion-positive tumors
Number of subjects: 24
Study 29538669 — intervention group
Group type: COMPARATOR
Intervention: RET negative tumors
Number of subjects: 24
Study 29538669 — intervention group
Group type: EXPERIMENTAL
Intervention: RET rearrangements
Number of subjects: 24
Study 29538761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency VMH-DBS
Number of subjects: 6
Study 29539287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection
Number of subjects: 546
Study 29539287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during first trimester
Number of subjects: 546
Study 29539287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during second trimester
Number of subjects: 546
Study 29539287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during third trimester
Number of subjects: 546
Study 29540222 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis treatment
Number of subjects: 6
Study 29540225 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron and/or folic acid supplementation
Number of subjects: 39
Study 29540225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial provision of free treatment
Number of subjects: 39
Study 29540225 — intervention group
Group type: EXPERIMENTAL
Intervention: Community education about the value of iron supplementation
Number of subjects: 39
Study 29540234 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap DS® (containing aspirin 100 mg, atenolol 50 mg, ramipril 5 mg, thiazide 12.5 mg, simvastatin 20 mg) taken as two capsules once daily for 12 months
Number of subjects: 120
Study 29540234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) with separate, individual secondary preventive medications prescribed at the physician's discretion
Number of subjects: 120
Study 29540234 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycap DS®
Number of subjects: 120
Study 29540234 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 120
Study 29540419 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Task Motivation Scale for Teachers (quantitative phase)
Number of subjects: 0
Study 29540419 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews (qualitative phase)
Number of subjects: 0
Study 29540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher (moderate-high)-intensity statins (n=868)
Number of subjects: 2444
Study 29540427 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower (low)-intensity statins (n=526)
Number of subjects: 2444
Study 29540427 — intervention group
Group type: COMPARATOR
Intervention: No statin (n=1050)
Number of subjects: 2444
Study 29540492 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage (LAA) closure
Number of subjects: 436
Study 29540492 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health status consideration during preprocedural evaluation
Number of subjects: 436
Study 29540575 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E isoforms (apoE2, apoE3, apoE4)
Number of subjects: 0
Study 29540603 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel, cisplatin, and cetuximab (TPC)
Number of subjects: 29
Study 29541050 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 360
Study 29541050 — intervention group
Group type: COMPARATOR
Intervention: Executive function, behavioral self-regulation, and school related well-being
Number of subjects: 360
Study 29541481 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Empowerment And Remote communication Linked by information technology (PEARL) intervention
Number of subjects: 628
Study 29541481 — intervention group
Group type: COMPARATOR
Intervention: No peer support (control group)
Number of subjects: 628
Study 29541875 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the dorsal dysgranular insula (dId) and other brain regions in males
Number of subjects: 37
Study 29541875 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the left dId and specific brain regions in males
Number of subjects: 37
Study 29541875 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivities (FCs) between the left dId and the right rostral anterior cingulate cortex in males
Number of subjects: 37
Study 29541969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic global electrical heterogeneity (GEH) measures including spatial QRST angle, spatial ventricular gradient magnitude, azimuth, elevation, and sum absolute QRST integral.
Number of subjects: 0
Study 29541969 — intervention group
Group type: EXPERIMENTAL
Intervention: GEH ECG risk score.
Number of subjects: 0
Study 29541969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular tachyarrhythmia event with appropriate ICD therapy.
Number of subjects: 0
Study 29541969 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy.
Number of subjects: 0
Study 29542012 — intervention group
Group type: EXPERIMENTAL
Intervention: LY IGlar
Number of subjects: 756
Study 29542012 — intervention group
Group type: COMPARATOR
Intervention: SA IGlar
Number of subjects: 756
Study 29542886 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA combined therapy
Number of subjects: 505
Study 29543115 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAC in middle-SES children
Number of subjects: 1157
Study 29543115 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAC in low-SES children
Number of subjects: 1157
Study 29543115 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-SES children with high PAC
Number of subjects: 1157
Study 29543115 — intervention group
Group type: COMPARATOR
Intervention: Low-SES children
Number of subjects: 1157
Study 29543490 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and adolescent reports of diabetes-specific family conflict
Number of subjects: 120
Study 29543490 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies between parent and adolescent reports of family conflict
Number of subjects: 120
Study 29543932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression or unacceptable toxic effects
Number of subjects: 259
Study 29543932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-positive tumors
Number of subjects: 259
Study 29543932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-negative tumors
Number of subjects: 259
Study 29543932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 259
Study 29544445 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin®) therapy
Number of subjects: 25
Study 29544454 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide 2 g orally once a day until disease progression or toxicity
Number of subjects: 0
Study 29544547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 260
Study 29544547 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 260
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with primary education
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Female employees and self-employed women
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged subjects
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a child in the household
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income individuals and manual workers
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with low education level
Number of subjects: 108183
Study 29544552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic categories and young adults
Number of subjects: 108183
Study 29544613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 29544613 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 29544613 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 29544699 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 2712
Study 29544699 — intervention group
Group type: COMPARATOR
Intervention: 12-month or longer DAPT
Number of subjects: 2712
Study 29545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg) every 2 weeks for up to 12 months
Number of subjects: 444
Study 29545231 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU/kg plasma-derived factor X (pdFX)
Number of subjects: 6
Study 29545283 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-omics integration using nine omics data blocks (mRNA, micro RNA, proteomes, and metabolomes)
Number of subjects: 52
Study 29545283 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of five to seven omics data blocks
Number of subjects: 52
Study 29545283 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven different combinations of four to seven omics platforms
Number of subjects: 52
Study 29545734 — intervention group
Group type: EXPERIMENTAL
Intervention: NORDIET-FFQ
Number of subjects: 81